PURIFIED COMPONENT OF BLUE-GREEN ALGAE AND METHOD OF USE
Disclosed herein are extracts of blue green algae, such as Aphanizomenon flos aquae, that are enriched for a selectin ligand, such as an L-selectin ligand. Selectin ligands isolated from blue-green algae cells are disclosed herein. Methods are described for isolating these selectin ligands. The purified selectin ligands are of use in inducing stem cell mobilization in a subject. Thus, methods for inducing stem cell isolation that include administering a therapeutically effective amount of the extract enriched form the selectin ligand, or an isolated selectin ligand, are disclosed herein.
1 . A composition comprising a first and a second component of Spirulina , wherein the first component consists of a dried form of a solvent extract of fresh, dehydrated, or preserved Spirulina , wherein the extract comprises a L-selectin ligand that binds specifically to L-selectin and inhibits fucoidan-mediated expression of the CXCR4 receptor, and where the solvent consists of water or buffered saline; and
wherein the second component consists of a dried form of a second solvent extract of fresh, dehydrated, or preserved Spirulina , wherein the second solvent comprises ethanol.
2 . A composition comprising a therapeutically effective amount of the composition of claim 1 in a pharmacologically acceptable carrier.
3 . The composition of claim 2 , wherein the second solvent extract is produced by suspending dried Spirulina in about 10 to about 20 percent ethanol at about 50° C. to about 60° C.
4 . The composition of claim 2 , comprising 1 gram to about 2 grams of the first component of Spirulina , and about 100 milligrams to about 500 milligrams of the second component of Spirulina.
5 . The composition of claim 4 , comprising about 1 gram of the first component of Spirulina , and about 150 milligrams of the second component of Spirulina.
6 . The composition of claim 1 , produced by the process of contacting a first amount of Spirulina in a solvent consisting of water or phosphate buffered saline for about half an hour to about 12 hours to produce a first extract;
removing solid material from the first extract;
drying the first extract to produce a solid composition comprising a L-selectin ligand;
incubating a second amount of Spirulina in 10 percent ethanol at about 50° C. for about one hour to produce la second extract;
removing solid material from the second extract;
drying the second extract to produce a solid form of the second extract; and
mixing a therapeutically effective amount of the solid composition comprising the L-selectin ligand and a therapeutically effective amount of the solid form of the second extract.
7 . A composition comprising about 1 gram of a first component of Spirulina and about 150 milligrams of a second component of Spirulina , wherein the first component consists of a dried form of a first solvent extract of fresh, dehydrated, or preserved Spirulina , wherein the first solvent extract comprises a L-selectin ligand that binds specifically to L-selectin and inhibits fucoidan-mediated expression of the CXCR4 receptor, and where the first solvent consists of water or buffered saline; and wherein the second component consists of a dried form of a second solvent extract of fresh, dehydrated, or preserved Spirulina , wherein the second solvent comprises about 10 percent to about 20 percent ethanol.
8 . The composition of claim 7 , where the first solvent consists of water.
9 . The composition of claim 7 , where the first solvent consists of buffered saline.
10 . The composition of claim 7 , wherein the second solvent comprises about 10 percent ethanol.
11 . The composition of claim 7 , wherein the second solvent comprises about 20 percent ethanol.
12 . The composition of claim 7 , wherein the composition is a solid.
13 . The composition of claim 12 wherein the solid is encapsulated.
14 . A liquid composition comprising 1 gram of the composition of claim 7 dissolved in water.
15 . A method of mobilizing hematopoietic stem cells in a subject, comprising:
administering to the subject a therapeutically effective amount of the composition of claim 1 , thereby mobilizing hematopoietic stem cells in the subject.
16 . The method of claim 15 , wherein the second solvent extract is produced by suspending dried Spirulina in about 10 to about 20 percent ethanol at about 50° C. to about 60° C.
17 . The method of claim 15 , wherein the composition comprises about 1 gram to about 2 grams of the first component of Spirulina , and about 100 milligrams to about 500 milligrams of the second component of Spirulina.
18 . The method of claim 15 , wherein the composition comprises about 1 gram of the first component of Spirulina , and about 150 milligrams of the second component of Spirulina.
19 . The method of claim 15 , wherein the hematopoietic stem cells express CD34, CD133, or both.
20 . The method of claim 19 , further comprising measuring the number of CD34+ stem cells in a sample from the subject.
21 . The method of claim 15 , wherein the subject is a human subject.
22 . The method of claim 15 , wherein the subject is healthy or has a chronic illness, traumatic injury, osteoporosis, Alzheimer's disease, cardiac infarction, Parkinson's disease, traumatic brain injury, multiple sclerosis, cirrhosis of the liver, a digestive system disorder, a nervous system disorder, a lymph system disorder, a cardiovascular system disorder, an endocrine system disorder, a degenerative disease or is immunosuppressed.
23 . The method of claim 15 , where stem cell homing is increased about 100% to about 500% in the subject as compared to a control.
24 . A method of mobilizing hematopoietic stem cells in a subject, comprising:
administering to the subject a therapeutically effective amount of the composition of claim 7 , thereby mobilizing hematopoietic stem cells in the subject.